Abstract:Our study unveils novel synthesis of indole‐based hydrazide/hydrazone derivatives as potential drugs for breast cancer treatment. Cytotoxicity of novel compounds on tumorigenic and non‐tumorigenic cells, alongside their effects on estrogen receptors and enzyme inhibition is investigated. Compounds EI 1, EI 4, and EI 11 are found promising against ER‐positive breast cancer, warranting further therapeutic exploration. Melatonin (N‐acetyl‐5‐methoxytryptamine, MLT) is suggested as a preventive agent and potential therapeutic option for breast cancer via its antioxidant as well as anticancer effects by modulating estrogen dependent and independent pathways. However, its rapid metabolic inactivation led scientists to discover novel MLT analogues. Therefore, a series of new indole‐based hydrazide/hydrazone derivatives were synthesized and characterized as MLT analogues in the present study. The initial aim is to investigate the cytotoxicity of novel 1‐ethyl indole hydrazone derivatives against two human breast cancer cells (MCF‐7 and MDA‐MB‐231) as well as a non‐tumorigenic human breast epithelial cell (MCF‐10A). Selective cytotoxic compounds for cancer cells are further investigated for their effects on selected targets; agonist/antagonist activity on estrogen receptor (ER) and inhibitory effects on aromatase and CYP1B1. Their potential antioxidant activity was also investigated by both cell based and cell free in vitro assays. Possible binding of the compounds to the selected targets is also explored by molecular modelling studies. Nonsubstituted compound E1 inhibited human aromatase and the CYP1B1 enzyme with IC50 values of 0.89 μM and 0.5 μM, respectively. Compounds EI 4 and EI 11 exhibited ER antagonist activity with IC50 values of 2.88 μM and 5.29 μM, respectively. Additionally, both EI 4 and EI 11 inhibited CYP1B1 enzyme within 60–100 nanomolar range. In conclusion among 19 tested derivatives EI 1, EI 4 and EI 11 affected either one or more targets besides their selective cytotoxic effect for MCF‐7 cells suggesting that they can be promising candidates in prevention/treatment of ER‐positive breast cancer. Further studies are needed to elucidate their metabolism, in vivo effects, and safety.

New enantioenriched β‐indolyl ketones as aromatase inhibitors: Unraveling heme–ligand interactions by MD simulation and MMPBSA analysis

Syntheses and Qsar Studies of Benzylimidazole Derivatives and Benzylcarbazole As Potential Aromatase Inhibitors

Discovery of potential 1,2,4-triazole derivatives as aromatase inhibitors for breast cancer: pharmacophore modelling, virtual screening, docking, ADMET and MD simulation

Molecular Docking, Synthesis and Biological Evaluation of New Benzimidazole‐Pyridine Derivatives as Potential Aromatase Inhibitor for the Treatment of Cancer

Synthesis, Docking Studies and Biological Activity of New Benzimidazole- Triazolothiadiazine Derivatives as Aromatase Inhibitor

Synthesis, In vitro and In silico Studies of Novel bis‐triazolopyridopyrimidines from Curcumin Analogues as Potential Aromatase Agents

Exploring okra-derived compounds as prospective aromatase inhibitors: a computational study for enhanced breast cancer therapy

Pyridine‐substituted thiazolylphenol derivatives: Synthesis, modeling studies, aromatase inhibition, and antiproliferative activity evaluation

Towards a New Generation of Hormone Therapies: Design, Synthesis and Biological Evaluation of Novel 1,2,3-Triazoles as Estrogen-Positive Breast Cancer Therapeutics and Non-Steroidal Aromatase Inhibitors

Design and synthesis new indole-based aromatase/iNOS inhibitors with apoptotic antiproliferative activity

Design, synthesis, molecular modeling, DFT, ADME and biological evaluation studies of some new 1,3,4-oxadiazole linked benzimidazoles as anticancer agents and aromatase inhibitors

Pharmacophore-based virtual screening, molecular docking, and molecular dynamics investigation for the identification of novel, marine aromatase inhibitors

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Unlocking the potential of aromatase inhibitors: recent advances in drug design, synthesis, docking activity, and in vitro bioactivity evaluations

Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents

Computational studies and structural insights for discovery of potential natural aromatase modulators for hormone-dependent breast cancer

Design, Synthesis, and Investigation of Anticancer and Antioxidant Potential of Novel Indole‐Based Melatonin Analogues in Breast Cancer

Molecular Docking Study of Isoxazole Indole Derivatives (B2A2 Series) as Promising Selective Estrogen Receptor Modulators & Anticancer Drugs

Computational prediction for designing novel ketonic derivatives as potential inhibitors for breast cancer: A trade-off between drug likeness and inhibition potency

Design and synthesis of triazole-functionalized isatin hybrids with potent anti-proliferative action against triple-negative breast cancer MDA-MB-231 cell line: a hybrid pharmacophore approach

Synthesis Of Indole‐Linked Thiadiazoles And Their Anticancer Action Against Triple‐Negative Breast Cancer